Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9

Bibliography

• Frank RN. Diabetic Retinopathy. N Engl J Med 2004;350:48-58
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BEK, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology 1994;101:68-76
   PubMed Web of Science ®Google Scholar
• Chew EY. Epidemiology of diabetic retinopathy. Hosp Med 2003;64:396-9
   PubMed Web of Science ®Google Scholar
• Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996;97:2883-90
   PubMed Web of Science ®Google Scholar
• Barber AJ, Lieth E, Khin SA, Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998;102:783-91
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Odenbach S. Effect of long-term administration of alpha lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004;53:3233-8
   PubMed Web of Science ®Google Scholar
• Feit-Leichman RA, Kinouchi R, Takeda M, Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Invest Ophthalmol Vis Sci 2005;46:4281-7
   PubMed Web of Science ®Google Scholar
• Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology. 1991;98:586-93
   Google Scholar
• Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011;21:193-215
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complication trial. Arch Ophthalm 1998;116:874-86
   PubMed Web of Science ®Google Scholar
• UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Invest Ophthalmol Vis Sci 2003;44:5327-34
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Kowluru V, Ho YS, Xiong Y. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic Biol Med 2006;41:1191-6
   PubMed Web of Science ®Google Scholar
• Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal 2010;13:797-805
   PubMed Web of Science ®Google Scholar
• Madsen-Bouterse S, Zhong Q, Mohammad G, Oxidative damage of mitochondrial DNA in diabetes, and its protection by manganese superoxide dismutase. Free Radic Res 2010;44:313-21
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Mohammad G, Dos Santos JM, Zhong Q. Abrogation of MMP9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 2011;60:3023-33
   PubMed Web of Science ®Google Scholar
• Santos JM, Mohammad G, Zhong Q, Kowluru RA. Diabetic retinopathy, superoxide damage and antioxidant. Curr Pharm Biotechnol 2011;12:352-61
   PubMed Web of Science ®Google Scholar
• Santos JM, Tewari S, Goldberg AFX, Kowluru RA. Mitochondria biogenesis and the development of diabetic retinopathy. Free Radic Biol Med 2011;51:1849-60
   PubMed Web of Science ®Google Scholar
• Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:3832-41
   PubMed Web of Science ®Google Scholar
• Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011;60:1304-13
   PubMed Web of Science ®Google Scholar
• Zhong Q, Kowluru RA. Diabetic retinopathy and damage to mitochondrial structure and transport machinery. Invest Ophthalmol Vis Sci 2011;52:8739-46
   PubMed Web of Science ®Google Scholar
• Nagase H, Woessner JJF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
   PubMed Web of Science ®Google Scholar
• Yang Y, Hill JW, Rosenberg GA. Multiple roles of metalloproteinases in neurological disorders. Prog Mol Biol Transl Sci 2011;99:241-63
   PubMed Web of Science ®Google Scholar
• Fridman R, Toth M, Chvyrkova I, Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003;22:153-66
   PubMed Web of Science ®Google Scholar
• Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271-90
   PubMed Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83
   PubMed Web of Science ®Google Scholar
• Liotta LA. Probing the depths of degradation: matrix metalloproteinase-2 and endometrial menstrual breakdown. J Clin Invest 1996;97:273-4
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006;11:1696-1701
   PubMed Web of Science ®Google Scholar
• Itoh Y, Seiki M. CMT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8
   PubMed Web of Science ®Google Scholar
• Dufour A, Sampson NS, Zucker S, Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 2008;217:643-51
   PubMed Web of Science ®Google Scholar
• Overall CM, Dean RA. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 2011;25:69-75
   Google Scholar
• Ovechkin AV, Tyagi N, Rodriguez WE, Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol 2005;99:2398-405
   PubMed Web of Science ®Google Scholar
• Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006;26:299-307
   PubMed Web of Science ®Google Scholar
• Van den Steen PE, Dubois B, Nelissen I, Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002;37:375-536
   PubMed Web of Science ®Google Scholar
• Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003;22:55-61
   PubMed Web of Science ®Google Scholar
• Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010;127:1081-95
   PubMed Web of Science ®Google Scholar
• Lee KW, Kim MS, Kang NJ, H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells. Int J Cancer 2006;119:1767-75
   PubMed Web of Science ®Google Scholar
• Yoon SO, Shin S, Lee HL, Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther 2006;5:2666-75
   PubMed Web of Science ®Google Scholar
• Kim SD, Yang SI, Kim HC, Inhibition of GSK-3beta mediates expression of MMP-9 through ERK1/2 activation and translocation of NF-kappaB in rat primary astrocyte. Brain Res 2007;1186:12-20
   PubMed Web of Science ®Google Scholar
• Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004;279:26287-99
   PubMed Web of Science ®Google Scholar
• Ma Z, Shah R, Chang M, Benveniste E. Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2004;24:5496-509
   PubMed Web of Science ®Google Scholar
• Mancini A, Di Battista JA. Transcriptional regulation of matrix metalloprotease gene expression in health and disease. Front Biosci 2006;11:423-46
   PubMed Web of Science ®Google Scholar
• Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26
   PubMed Web of Science ®Google Scholar
• Robert I, Aussems M, Keutgens A, Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes. Oncogene 2009;28:1626-8
   PubMed Web of Science ®Google Scholar
• Liu P, Wilson MJ. miR-520c and miR-373 target mTOR and SIRT1, activate the Ras/Raf/MEK/Erk pathway and NF-?B, with up-regulation of MMP9 in human fibrosarcoma cells. J Cell Physiol 2010; Epub ahead of print
   Web of Science ®Google Scholar
• Hasebe Y, Egawa K, Shibanuma M, Nose K. Induction of matrix metalloproteinase gene expression in an endothelial cell line by direct interaction with malignant cells. Cancer Sci 2007;98:58-67
   PubMed Web of Science ®Google Scholar
• Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004;37:768-84
   PubMed Web of Science ®Google Scholar
• Pfeilschifter J, Eberhardt W, Huwiler A. Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. Eur J Pharmacol 2001;429:279-86
   PubMed Web of Science ®Google Scholar
• Valentin F, Bueb JL, Kieffer P, Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells. Fundam Clin Pharmacol 2005;19:661-7
   PubMed Web of Science ®Google Scholar
• Moshal KS, Singh M, Sen U, Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006;11:H2825-35
   Google Scholar
• Moshal KS, Tipparaju SM, Vacek TP, Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008;295:H890-7
   PubMed Web of Science ®Google Scholar
• Zhoua H-Z, Maa X, Graye MO, Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun 2007;358:189-95
   PubMed Web of Science ®Google Scholar
• Amin P, Singh M, Singh K. beta-Adrenergic receptor-stimulated cardiac myocyte apoptosis: Role of beta1 integrin. Signal Transduct 2011;2011:179057
   Google Scholar
• Kwan JA, Schulze CJ, Wang W, Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004;18:690-2
   PubMed Web of Science ®Google Scholar
• Dawson VL, Dawson TM. Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 2004;36:287-94
   PubMed Web of Science ®Google Scholar
• Rosenberger D, Gargoum R, Tyagi N, Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice. Nutr Metab Cardiovasc Dis 2011;21:492-8
   PubMed Web of Science ®Google Scholar
• Tyagi SC, Rodriguez W PA, Roberts AM, Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling. J Cardiovasc Pharmacol Ther 2005;10:1-10
   PubMed Web of Science ®Google Scholar
• Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35:1-10
   PubMed Web of Science ®Google Scholar
• Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest 2010;90:1365-72
   PubMed Web of Science ®Google Scholar
• Mohammad G, Kowluru R. Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinases-9. J Cell Physiol 2011; Epub ahead of print
   Google Scholar
• Das A, McGuire PG, Eriqat C, Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-13
   PubMed Web of Science ®Google Scholar
• Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol 2005;28:9
   Google Scholar
• McKittrick IB, Bogaert Y, Nadeau K, Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol 2011;301:F326-33
   Google Scholar
• Williams JM, Zhang J, North P, Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 2011;300:F983-8
   PubMed Web of Science ®Google Scholar
• Jin M, Kashiwagi K, Iizuka Y, Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001;21:28-33
   PubMed Web of Science ®Google Scholar
• Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005;85:567-607
   Google Scholar
• Yang R, Liu H, Williams I, Chaqour B. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann NY Acad Sci 2007;1103:196-201
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Radic Biol Med 2009;46:1677-85
   PubMed Web of Science ®Google Scholar
• Hoffmann S, He S, Ehren M, MMP-2 and MMP-9 secretion is stimulated by angiogenic molecules found in choroidal neovascular membranes. Retina 2006;26:454-61
   PubMed Web of Science ®Google Scholar
• Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007;56:2380-7
   PubMed Web of Science ®Google Scholar
• Noda K, Ishida S, Inoue M, Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2003;44:2163-70
   PubMed Web of Science ®Google Scholar
• Barth JL, Yu Y, Song W, Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 2007;50:2200-8
   PubMed Web of Science ®Google Scholar
• Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999;117:498-503
   PubMed Web of Science ®Google Scholar
• Hu J, Van den Steen P, Sang Q-X, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-98
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Xu ZZ, Wang X, Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008;14:331-6
   PubMed Web of Science ®Google Scholar
• Asahi M, Asahi K, Jung JC, Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:1681-9
   PubMed Web of Science ®Google Scholar
• Chadzinska M, Baginski P, Kolaczkowska E, Expression profiles of matrix metalloproteinase 9 in teleost fish provide evidence for its active role in initiation and resolution of inflammation. Immunology 2008;125:601-10
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2
   PubMed Web of Science ®Google Scholar
• Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 2004;88:1343-7
   PubMed Web of Science ®Google Scholar
• Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after re-institution of good glycemic control: novel mechanism for metabolic memory. J Diabetes Complications 2010;24:55-63
   PubMed Web of Science ®Google Scholar
• Joussen AM, Murata T, Tsujikawa A, Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001;158:147-52
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 2004;45:4161-6
   PubMed Web of Science ®Google Scholar
• Behl Y, Krothapalli P, Desta T, Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol 2008;172:1411-18
   PubMed Web of Science ®Google Scholar
• Lee CZ, Xue Z, Zhu Y, Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke 2007;38:2563-8
   PubMed Web of Science ®Google Scholar
• Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997;29:354-62
   PubMed Web of Science ®Google Scholar
• Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med 2009;5:13-25
   PubMed Web of Science ®Google Scholar
• Ishizaki E, Takai S, Ueki M, Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006;141:129-34
   PubMed Web of Science ®Google Scholar
• Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221-3
   PubMed Web of Science ®Google Scholar
• Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000;77:S113-19
   Google Scholar
• Chung AW, Hsiang YN, Matzke LA, Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006;99:140-8
   PubMed Web of Science ®Google Scholar
• Das S, Mandal M, Chakraborti T, Isolation of MMP-2 from MMP-2/TIMP-2 complex: characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane. Biochim Biophys Acta 2004;1674:158-74
   PubMed Web of Science ®Google Scholar
• Federici TJ. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease. Pharmacol Res 2011;64:614-23
   PubMed Web of Science ®Google Scholar
• Hussain AA, Lee Y, Zhang JJ, Marshall J. Disturbed matrix metalloproteinase activity of Bruch's membrane in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:4459-66
   PubMed Web of Science ®Google Scholar
• Ghanem AA, Arafa LF, El-Baz A. Connective tissue growth factor and tissue inhibitor of matrix metalloproteinase-2 in patients with exfoliative glaucoma. Curr Eye Res 2011;36:540-5
   PubMed Web of Science ®Google Scholar
• Sambursky R, O'Brien TP. MMP-9 and the perioperative management of LASIK surgery. Curr Opin Ophthalmol 2011;22:294-303
   PubMed Web of Science ®Google Scholar
• Alapure BV, Praveen MR, Gajjar D, Matrix metalloproteinase-9 activity in human lens epithelial cells of cortical, posterior subcapsular, and nuclear cataracts. J Cataract Refract Surg 2008;34:2063-7
   PubMed Web of Science ®Google Scholar
• Wang X, Li KF, Adams E, Van Schepdael A. Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Curr Drug Metab 2011;12:395-410
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Eckhardt SC. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93
   PubMed Web of Science ®Google Scholar
• Yiqin Y, Meilin X, Jie X, Keping Z. Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. Inflammation 2009;32:233-41
   PubMed Web of Science ®Google Scholar
• Samtani S, Amaral J, Campos MM, Doxycycline-977 mediated inhibition of choroidal neovascularization. Invest Ophthalmol Vis Sci 2009;50:5098-106
   PubMed Web of Science ®Google Scholar
• Reddy AB, Ramana KV, Srivastava S, Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells. Endocrinology 2005;150:63-74
   Google Scholar
• Ozerdem U, Mach-Hofacre B, Cheng L, The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res 2000;20:447-53
   PubMed Web of Science ®Google Scholar
• Bhatt LK, Addepalli V. Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res 2010;2:181-9
   PubMed Web of Science ®Google Scholar